EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...
GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...
GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...
By analyzing nasal polyp tissue from patients ... exacerbating tissue damage and amplifying inflammation. These granzyme K-producing T cells continually migrate from peripheral blood into nasal ...
Study uncovers a pathogenic subset of memory T-cells that promote tissue inflammation and highlights a potential target for treating nasal polyps and other inflammatory airway diseases.
18-20 CRSwNP is caused by inflammation of the nasal lining that can lead to soft tissue growths, known as nasal polyps. 9,12 People with CRSwNP experience symptoms such as nasal obstruction, loss of ...
Inflammation can occur because of conditions ... You could have an underlying medical condition, such as nasal polyps. Also, it’s best to talk with a doctor if you have severe or concerning ...
Antrochoanal polyps are unilateral nasal polyps that originate from the maxillary sinus and extend into the choana, which is the space behind the nose where it connects to the throat. These polyps ...